In Brief This Week: Myriad Genetics, Alliance Global Group; Eutropics; Affymetrix; Courtagen; NuGen | GenomeWeb

NEW YORK (GenomeWeb) – The Alliance Global Group and Myriad Genetics GmbH have reached a deal to promote the EndoPredict prognostic test for breast cancer. Myriad Genetics GmbH, the international subsidiary of Myriad Genetics, and Sividon Diagnostics entered into an agreement in January to co-market Sividon's EndoPredict test outside the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.